Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

Executive Summary

After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.


Related Content

Big Pharma’s Partnering Process: An Insight Into The Nitty-Gritty
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Hanmi Toughens Controls As Employees Arrested For Insider Trading
Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious
Korean Authorities Mull New Steps, Probe Over Olmutinib Events
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Roche Sees Cancer Combos Start To Deliver
Korean Pharma Taking To Open Innovation In Diverse Ways


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts